Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neuroendocrine Tumors × 177Lu-octreotate × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 6 lutetium Lu 177 dotatate 5 lanreotide 4 Octreotide 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 amino-acid, glucose, and electrolyte solution 3 Capecitabine 3 surufatinib 2 fluorodopa F 18 2 Introns 2 copper dotatate CU-64 1 cabozantinib 1 X-Rays 1 Temozolomide 1 Sunitinib 1 Specimen Handling 1 Somatostatin 1 Serotonin 1 Salts 1 Phantoms, Imaging 1 Oxaliplatin 1 Magnetic Resonance Spectroscopy 1 Lutetium-177 1 Lutetium 1 Leucovorin 1 Interferon alpha-2 1 Immunoglobulin G 1 Ga(III)-DOTATOC 1 Furosemide 1 Folfox protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡